Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4298092

GLOFITAMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available
ChEMBL ↗

Basic Information

ChEMBL ID CHEMBL4298092
Name GLOFITAMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

Columvi Glofitamab Glofitamab-gxbm RG-6026 RG6026 RO-7082859 Ro7082859
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
7
Known Names
6
Indications
2
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2023
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral

Flags

Black Box Warning
USAN Stem -mab
USAN Year 2020

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
B-lymphocyte antigen CD20 binding agent BINDING AGENT B-lymphocyte antigen CD20 ✓ ✓
T cell surface glycoprotein CD3 binding agent BINDING AGENT T cell surface glycoprotein CD3 ✓ ✓

Indications

Lymphoma, Large B-Cell, Diffuse Neoplasms Lymphoma Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Non-Hodgkin

ATC Classification

L01FX28
glofitamab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS

Drug Warnings

Black Box Warning
immune system toxicity
Country: United States

Data from ChEMBL 36 via Core Engine